Skip to main content

Infertility, Female

9
Pipeline Programs
18
Companies
28
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
2
1
0
1
3
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

17 companies ranked by most advanced pipeline stage

Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
CFAPhase 4
MSD
MSDIreland - Ballydine
1 program
1
CFAPhase 4
Eppendorf
EppendorfGermany - Hamburg
1 program
1
Dydrogesterone Oral TabletPhase 41 trial
Active Trials
NCT03677336Completed30Est. Aug 2020
Human BioSciences
Human BioSciencesWV - Martinsburg
4 programs
1
2
1
Caloric RestrictionPhase 31 trial
G-CSFPhase 1/21 trial
G-CSFPhase 1/21 trial
MicrodialysisPhase 1
Active Trials
NCT01202656Completed129Est. Jun 2013
NCT01202643Terminated12Est. Feb 2013
NCT02432209Completed379Est. May 2020
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
2 programs
1
1
Estradiol PatchesPhase 21 trial
MicrodialysisPhase 11 trial
Active Trials
NCT01817400Completed10Est. Dec 2014
NCT06686537Recruiting20Est. Dec 2026
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
7 programs
MENOPUR CohortN/A1 trial
Other: Non interventionN/A1 trial
A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mLPHASE_11 trial
Degarelix mid-luteal, 2.5 mgPHASE_21 trial
FE 999049PHASE_31 trial
+2 more programs
Active Trials
NCT04814940Withdrawn0Est. Sep 2023
NCT04654039Completed728Est. Oct 2023
NCT04902131Completed95Est. Aug 2022
+4 more trials
Genomic Prediction
Genomic PredictionNJ - Hackettstown
3 programs
Preimplantation genetic testing for aneuploidyN/A1 trial
Preimplantation genetic testing for aneuploidyN/A1 trial
Spent media collectionN/A1 trial
Active Trials
NCT06141135Recruiting240Est. Nov 2026
NCT04167748Recruiting240Est. Dec 2026
NCT04628507Not Yet Recruiting200Est. Dec 2027
Genesis Therapeutics
Genesis TherapeuticsCA - Burlingame
2 programs
Autologous PRP intra ovarian infusionPHASE_2_31 trial
Autologous Platelet Rich PlasmaPHASE_2_31 trial
Active Trials
NCT03916978RecruitingEst. Jul 2026
NCT03951194UnknownEst. Jul 2025
Merck & Co.
Merck & Co.RAHWAY, NJ
2 programs
Pre-treatment with rLHPHASE_31 trial
CFAPHASE_41 trial
Active Trials
NCT03741699Completed88Est. May 2024
NCT03755973Completed24Est. May 2023
Innovation Pharmaceuticals
1 program
EmbryORP®N/A1 trial
Active Trials
NCT05919186Completed293Est. May 2022
Clarity Pharmaceuticals
Clarity PharmaceuticalsAustralia - Eveleigh
1 program
Follicle ClarityN/A1 trial
Active Trials
NCT04545918Unknown80Est. May 2021
ConvaTec
ConvaTecNJ - Bridgewater
1 program
IVF with the Neria™ Guard Subcutaneous CatheterN/A1 trial
Active Trials
NCT05505474Unknown100Est. Dec 2024
Lo.Li. Pharma
Lo.Li. PharmaItaly - Rome
1 program
Inofolic PlusN/A1 trial
Active Trials
NCT01290432Completed15Est. Feb 2012
Overture Life
Overture LifeFL - Coral Gables
1 program
Investigational device named ICSIAN/A1 trial
Active Trials
NCT05633316Unknown10Est. Nov 2024
Genomics
GenomicsUK - Oxford
1 program
Timelapse incubation and PGTN/A1 trial
Active Trials
NCT06419127Enrolling By Invitation2,000Est. Jun 2033
Gedeon Richter
Gedeon RichterHungary - Budapest
1 program
ULIPRISTAL ACETATEN/A1 trial
Active Trials
NCT03349190Completed127Est. Jan 2019
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
QL1012DPHASE_11 trial
Active Trials
NCT06864793Active Not Recruiting48Est. Apr 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Merck & Co.CFA
EppendorfDydrogesterone Oral Tablet
Ferring PharmaceuticalsFE 999049
Ferring PharmaceuticalsFE 999049 + GnRH agonist
Merck & Co.Pre-treatment with rLH
Ferring PharmaceuticalsFollitropin delta
Human BioSciencesCaloric Restriction
Genesis TherapeuticsAutologous Platelet Rich Plasma
Genesis TherapeuticsAutologous PRP intra ovarian infusion
Colorado TherapeuticsEstradiol Patches
Ferring PharmaceuticalsDegarelix mid-luteal, 2.5 mg
Human BioSciencesG-CSF
Human BioSciencesG-CSF
Qilu PharmaceuticalQL1012D
Ferring PharmaceuticalsA MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL

Showing 15 of 28 trials with date data

Clinical Trials (28)

Total enrollment: 6,279 patients across 28 trials

Effect of Different Ovarian Stimulation Protocols on Endometrial Receptivity

Start: Jan 2020Est. completion: May 202324 patients
Phase 4Completed
NCT03677336EppendorfDydrogesterone Oral Tablet

Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI

Start: May 2019Est. completion: Aug 202030 patients
Phase 4Completed

A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China

Start: Mar 2024Est. completion: May 2025301 patients
Phase 3Completed
NCT03809429Ferring PharmaceuticalsFE 999049 + GnRH agonist

Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)

Start: Apr 2019Est. completion: Feb 2022437 patients
Phase 3Completed
NCT03741699Merck & Co.Pre-treatment with rLH

Recombinant LH Prior to Ovarian Stimulation in Poor Ovarian Responders (PRE-LH)

Start: Feb 2019Est. completion: May 202488 patients
Phase 3Completed

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)

Start: Oct 2018Est. completion: Dec 2020588 patients
Phase 3Completed
NCT02432209Human BioSciencesCaloric Restriction

Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility

Start: Aug 2015Est. completion: May 2020379 patients
Phase 3Completed
NCT03951194Genesis TherapeuticsAutologous Platelet Rich Plasma

Autologous Platelet Rich Plasma (PRP) Intra Ovarian Infusion in Perimenopausal Women

Start: Jun 2019Est. completion: Jul 2025
Phase 2/3Unknown
NCT03916978Genesis TherapeuticsAutologous PRP intra ovarian infusion

Autologous PRP Intra Ovarian Infusion to Restore Ovarian Function in Menopausal Women

Start: May 2019Est. completion: Jul 2026
Phase 2/3Recruiting

Convergent Mechanisms Underlying Reprometabolic Syndrome in Women

Start: Feb 2025Est. completion: Dec 202620 patients
Phase 2Recruiting
NCT00434122Ferring PharmaceuticalsDegarelix mid-luteal, 2.5 mg

Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix

Start: Mar 2007Est. completion: Dec 200785 patients
Phase 2Completed

Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)

Start: Sep 2010Est. completion: Jun 2013129 patients
Phase 1/2Completed

Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF

Start: Sep 2010Est. completion: Feb 201312 patients
Phase 1/2Terminated

Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers

Start: Apr 2025Est. completion: Apr 202648 patients
Phase 1Active Not Recruiting
NCT04902131Ferring PharmaceuticalsA MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL

A Study Comparing MENOPUR in a Pen Formulation With a Powder and Solvent Formulation in Healthy Women

Start: Nov 2021Est. completion: Aug 202295 patients
Phase 1Completed

Mediators of Abnormal Reproductive Function in Obesity (MARO)

Start: Mar 2013Est. completion: Dec 201410 patients
Phase 1Completed
NCT04628507Genomic PredictionSpent media collection

Cell Free Preimplantation Genetic Testing

Start: Jun 2026Est. completion: Dec 2027200 patients
N/ANot Yet Recruiting
NCT06419127GenomicsTimelapse incubation and PGT

Embryo Assessment Utilizing Timelapse Imaging in Conjunction With Preimplantation Genetic Testing for Aneuploidy With Next Generation Sequencing

Start: Jan 2025Est. completion: Jun 20332,000 patients
N/AEnrolling By Invitation
NCT06141135Genomic PredictionPreimplantation genetic testing for aneuploidy

GEnetic Testing in Elective Single Embryo Transfer (GETSET): A Randomized Clinical Trial

Start: Nov 2023Est. completion: Nov 2026240 patients
N/ARecruiting
NCT05505474ConvaTecIVF with the Neria™ Guard Subcutaneous Catheter

Use of a Subcutaneous Catheter for Controlled Ovarian Stimulation

Start: Nov 2023Est. completion: Dec 2024100 patients
N/AUnknown
NCT05633316Overture LifeInvestigational device named ICSIA

Automated Intracytoplasmic Sperm Injection (ICSIA)

Start: Dec 2022Est. completion: Nov 202410 patients
N/AUnknown

Retrospective Analysis of Real-world Data From Medical Records on the Use of MENOPUR for Infertility Treatment

Start: Sep 2022Est. completion: Sep 20230
N/AWithdrawn

Effects of Antioxidant Supplementation of Culture Media on IVF Embryos

Start: Oct 2021Est. completion: May 2022293 patients
N/ACompleted
NCT04167748Genomic PredictionPreimplantation genetic testing for aneuploidy

Preimplantation Genetic Testing in Women of Advanced Maternal Age

Start: Mar 2021Est. completion: Dec 2026240 patients
N/ARecruiting

Convolutional Neural Network in Ovarian Follicle Identification

Start: Feb 2021Est. completion: May 202180 patients
N/AUnknown
NCT04654039Ferring PharmaceuticalsOther: Non intervention

Post-Marketing Surveillance (PMS) Protocol of REKOVELLE Pre-Filled Pen (Follitropin Delta)

Start: Oct 2020Est. completion: Oct 2023728 patients
N/ACompleted
NCT03349190Gedeon RichterULIPRISTAL ACETATE

Impact of Esmya on Fertility to Infertile Women With Fibroids Managed With Assisted Reproduction Techniques

Start: Dec 2017Est. completion: Jan 2019127 patients
N/ACompleted

The Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve Parameters in Subfertile Women

Start: Feb 2011Est. completion: Feb 201215 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
4 actively recruiting trials targeting 6,279 patients
18 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.